A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 9 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-21.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 50th largest by enrollment, is one of 14 that started in 2010, is one of 65 in phase 3, and was the 30th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 14 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 78th largest by enrollment of the 141 interventional ones that give a count, is one of 26 that started in 2010, is one of 85 in phase 3, and was the 75th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single-arm, open-label, multicenter study evaluated the safety and tolerability and the efficacy in reducing disease activity of tocilizumab [RoActemra/Actemra] as monotherapy or in combination with methotrexate in patients with active moderate to severe rheumatoid arthritis (RA). Patients were eligible to participate in this study if they are currently experiencing an inadequate response to a stable dose of a non-biologic disease-modifying antirheumatic drug (DMARD). Patients received 8 mg/kg tocilizumab [RoActemra/Actemra] as an intravenous infusion every 4 weeks for a total of 6 infusions. The anticipated time on study treatment was 24 weeks. The target sample size was 50-200 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received an 8 mg/kg tocilizumab intravenous (IV) infusion once every 4 weeks for 24 weeks (6 infusions). Participants taking concomitant methotrexate (MTX) at Baseline remained on a stable dose as per standard of care at the Investigator's discretion.
Drug: tocilizumab [RoActemra/Actemra] · Drug: Methotrexate
Drug page: Tocilizumab
8 mg/kg intravenous infusion every 4 weeks.
methotrexate as per standard of care in clinical practice.
Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Low Disease Activity
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.
Time frame: Baseline to Week 24 (Weeks 4, 8, 12, 16, 20, 24)
Time to DAS28 Low Disease Activity
Time to DAS28 Low Disease Activity was defined as the time in days from the first infusion of study drug to the achievement of a DAS28 Score \<3.2 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.
Time frame: 24 Weeks
Percentage of Participants Achieving DAS28 Clinically Significant Improvement
DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24
Time to DAS28 Clinically Significant Improvement
Time to DAS28 Clinically Significant Improvement was the Time in days from the first infusion of study drug to the achievement of a DAS28 score reduction of at least 1.2 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.
Time frame: 24 Weeks
Percentage of Participants Achieving DAS28 Remission
DAS28 Remission was defined as a DAS28 score \< 2.6 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.
Time frame: Weeks 4, 8, 12, 16, 20, 24
Time to DAS28 Remission
Time to DAS28 Remission was the Time in days from the first infusion of study drug to the achievement of a DAS28 score \< 2.6 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.
Time frame: 24 Weeks
Disease Activity Score 28 (DAS28)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.
Time frame: Weeks 4, 8, 12, 16, 20, 24
C-Reactive Protein (CRP)
Blood was collected for C-Reactive Protein (CRP), a test for inflammation, at Weeks 4, 8, 12, 16, 20 and 24 and was analyzed at a central laboratory. The serum concentration of CRP was measured in milligrams/deciliter (mg/dL).
Time frame: Weeks 4, 8, 12, 16, 20, 24
Erythrocyte Sedimentation Rate (ESR)
Blood was collected for Erythrocyte Sedimentation Rate (ESR), a test to assess inflammation, at Weeks 4, 8, 12, 16, 20, 24 and was analyzed at a central laboratory. ESR was measured in millimeters/hour (mm/hr).
Time frame: Weeks 4, 8, 12, 16, 20, 24
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: 24 Weeks
Number of Participants With AE and SAE Related Discontinuation
The number of participants who stopped using the study drug because of an AE or a SAE. An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: 24 Weeks
Number of Participants With Serious Infections
A serious infection was an infection that qualified as a Serious Adverse Event (SAE). A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: 24 Weeks
Number of Participants With Elevated AST (SGOT) and ALT (SGPT)
Blood was collected for aspartate aminotransferase (serum glutamic oxaloacetic transaminase) \[AST/SGOT\] and alanine aminotransferase (serum glutamic pyruvic transaminase) \[ALT/SGPT\], liver function tests, and were analyzed at a central laboratory. The number of participants with High AST (SGOT) or ALT (SGPT) levels at Week 24 is reported.
Time frame: Week 24
Number of Participants With Elevated Total Cholesterol According to ATPIII Guidelines
Blood samples were collected for Total Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the Total Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Desirable ( \< 200), Borderline High (200- 239) or High (≥ 240). The number of participants categorized Borderline High or High at each time-point is reported.
Time frame: Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24
Number of Participants With Elevated HDL Cholesterol According to ATPIII Guidelines
Blood samples were collected for High Density Lipoprotein (HDL) Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the HDL Total Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Low (\< 40) or High (≥ 60). The number of participants with category High at each time-point is reported.
Time frame: Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24
Number of Participants With Elevated LDL Cholesterol According to ATPIII Guidelines
Blood samples were collected for Low Density Lipoprotein (LDL) Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the LDL Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Optimal (\< 100), Near Optimal/Above Optimal (100- 129), Borderline High (130- 159), High (160-189) or Very High (≥ 190). The number of participants categorized Borderline High, High or Very High at each time-point is reported.
Time frame: Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24
Number of Participants With Elevated Triglyceride According to ATPIII Guidelines
Blood samples were collected for Triglyceride and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the Triglyceride level in milligram/deciliter (mg/dL) was categorized as: Normal (\< 150), Borderline High (150- 199), High (200- 499) or Very High (≥ 500). The number of participants categorized Borderline High, High or Very High at each time-point is reported.
Time frame: Weeks 0 (Baseline), 4, 8, 12, 16, 20, 24
107 participants were enrolled from 11 centers in Egypt, 2 centers were prematurely terminated.
| Milestone | Tocilizumab | Tocilizumab + MTX |
|---|---|---|
| Started | 30 | 77 |
| Received study drug | 29 | 76 |
| Completed | 22 | 65 |
| Not completed | 8 | 12 |
| Withdrew: Patient withdrew consent | 0 | 1 |
| Withdrew: Adverse event | 2 | 4 |
| Withdrew: Protocol violation | 5 | 4 |
| Withdrew: Investigator's request | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Miscellaneous reason | 0 | 1 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.
| percentage of participants | Tocilizumab | Tocilizumab + MTX |
|---|---|---|
| Week 4 | 27.59 | 18.42 |
| Week 8 | 34.48 | 40.79 |
| Week 12 | 34.48 | 38.16 |
| Week 16 | 44.83 | 47.37 |
| Week 20 | 62.07 | 57.89 |
| Week 24 | 58.62 | 59.21 |
Time to DAS28 Low Disease Activity was defined as the time in days from the first infusion of study drug to the achievement of a DAS28 Score \<3.2 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.
| days | Tocilizumab | Tocilizumab + MTX |
|---|---|---|
| Time to DAS28 Low Disease Activity | 107.2 (84.57 to 129.78) | 100.2 (87.49 to 112.93) |
DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.
| percentage of participants | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Week 4 | 62.07 | 73.68 |
| Week 8 | 75.86 | 86.84 |
| Week 12 | 75.86 | 90.79 |
| Week 16 | 79.31 | 92.11 |
| Week 20 | 82.76 | 90.79 |
| Week 24 | 86.20 | 96.10 |
Time to DAS28 Clinically Significant Improvement was the Time in days from the first infusion of study drug to the achievement of a DAS28 score reduction of at least 1.2 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.
| days | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Time to DAS28 Clinically Significant Improvement | 59.9 (40.20 to 79.53) | 41.6 (34.51 to 48.76) |
DAS28 Remission was defined as a DAS28 score \< 2.6 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.
| percentage of participants | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Week 4 | 17.24 | 9.21 |
| Week 8 | 31.03 | 23.68 |
| Week 12 | 31.03 | 27.63 |
| Week 16 | 34.48 | 34.21 |
| Week 20 | 41.38 | 40.79 |
| Week 24 | 48.28 | 40.79 |
Time to DAS28 Remission was the Time in days from the first infusion of study drug to the achievement of a DAS28 score \< 2.6 units. The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.
| days | Tocilizumab | Tocilizumab + MTX |
|---|---|---|
| Time to DAS28 Remission | 115.9 (94.24 to 137.49) | 120.5 (108.38 to 132.57) |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Low Disease Activity was defined as a DAS28 score of \< 3.2.
| score on a scale | Tocilizumab | Tocilizumab + MTX |
|---|---|---|
| Week 4 (n=24,75) | 4.17 ± 1.45 | 4.48 ± 1.47 |
| Week 8 | 3.72 ± 1.71 | 3.68 ± 1.60 |
| Week 12 | 3.37 ± 1.62 | 3.54 ± 1.45 |
| Week 16 | 3.25 ± 1.54 | 3.21 ± 1.43 |
| Week 20 | 2.86 ± 1.50 | 3.11 ± 1.44 |
| Week 24 | 2.51 ± 1.50 | 3.06 ± 1.51 |
Blood was collected for C-Reactive Protein (CRP), a test for inflammation, at Weeks 4, 8, 12, 16, 20 and 24 and was analyzed at a central laboratory. The serum concentration of CRP was measured in milligrams/deciliter (mg/dL).
| mg/L | Tocilizumab | Tocilizumab + MTX |
|---|---|---|
| Week 4 | 13.04 ± 24.90 | 12.28 ± 28.37 |
| Week 8 (n=25,74) | 14.74 ± 35.74 | 6.24 ± 13.39 |
| Week 12 | 9.35 ± 17.29 | 6.89 ± 15.84 |
| Week 16 | 4.38 ± 9.98 | 3.87 ± 11.01 |
| Week 20 | 7.92 ± 15.07 | 4.20 ± 12.11 |
| Week 24 | 6.99 ± 13.64 | 3.82 ± 13.39 |
Blood was collected for Erythrocyte Sedimentation Rate (ESR), a test to assess inflammation, at Weeks 4, 8, 12, 16, 20, 24 and was analyzed at a central laboratory. ESR was measured in millimeters/hour (mm/hr).
| mm/hr | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Week 4 (n=24,27) | 21.08 ± 22.27 | 20.37 ± 25.66 |
| Week 8 | 17.18 ± 21.54 | 13.79 ± 18.52 |
| Week 12 | 14.12 ± 15.10 | 16.41 ± 22.25 |
| Week 16 | 15.80 ± 23.65 | 13.88 ± 18.02 |
| Week 20 | 16.32 ± 25.44 | 14.28 ± 20.42 |
| Week 24 | 16.32 ± 22.43 | 16.40 ± 22.26 |
An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| participants | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| AEs | 29 | 76 |
| SAEs | 5 | 12 |
The number of participants who stopped using the study drug because of an AE or a SAE. An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| participants | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Discontinuation due to AE | 8 | 7 |
| Discontinuation due to SAE | 5 | 6 |
A serious infection was an infection that qualified as a Serious Adverse Event (SAE). A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| participants | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Number of Participants With Serious Infections | 1 | 1 |
Blood was collected for aspartate aminotransferase (serum glutamic oxaloacetic transaminase) \[AST/SGOT\] and alanine aminotransferase (serum glutamic pyruvic transaminase) \[ALT/SGPT\], liver function tests, and were analyzed at a central laboratory. The number of participants with High AST (SGOT) or ALT (SGPT) levels at Week 24 is reported.
| participants | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| ALT (SGPT) | 3 | 6 |
| AST (SGOT) | 3 | 8 |
Blood samples were collected for Total Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the Total Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Desirable ( \< 200), Borderline High (200- 239) or High (≥ 240). The number of participants categorized Borderline High or High at each time-point is reported.
| participants | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Week 0 | 10 | 25 |
| Week 4 | 16 | 41 |
| Week 8 | 10 | 34 |
| Week 12 | 9 | 30 |
| Week 16 | 10 | 36 |
| Week 20 | 7 | 35 |
| Week 24 | 9 | 30 |
Blood samples were collected for High Density Lipoprotein (HDL) Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the HDL Total Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Low (\< 40) or High (≥ 60). The number of participants with category High at each time-point is reported.
| participants | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Week 0 | 4 | 20 |
| Week 4 | 10 | 34 |
| Week 8 | 2 | 26 |
| Week 12 | 6 | 22 |
| Week 16 | 5 | 19 |
| Week 20 | 2 | 20 |
| Week 24 | 5 | 20 |
Blood samples were collected for Low Density Lipoprotein (LDL) Cholesterol and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the LDL Cholesterol level in milligram/deciliter (mg/dL) was categorized as: Optimal (\< 100), Near Optimal/Above Optimal (100- 129), Borderline High (130- 159), High (160-189) or Very High (≥ 190). The number of participants categorized Borderline High, High or Very High at each time-point is reported.
| participants | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Week 0 | 9 | 24 |
| Week 4 | 11 | 35 |
| Week 8 | 7 | 21 |
| Week 12 | 8 | 27 |
| Week 16 | 9 | 31 |
| Week 20 | 7 | 33 |
| Week 24 | 8 | 29 |
Blood samples were collected for Triglyceride and were sent to a central laboratory for analysis. According to Adult Treatment Profile III (ATPIII) guidelines the Triglyceride level in milligram/deciliter (mg/dL) was categorized as: Normal (\< 150), Borderline High (150- 199), High (200- 499) or Very High (≥ 500). The number of participants categorized Borderline High, High or Very High at each time-point is reported.
| participants | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Week 0 | 4 | 7 |
| Week 4 | 6 | 15 |
| Week 8 | 4 | 12 |
| Week 12 | 5 | 15 |
| Week 16 | 6 | 15 |
| Week 20 | 8 | 16 |
| Week 24 | 6 | 16 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab Monotherapy | — | 5/29 (17.2%) | 29/29 (100%) |
| Tocilizumab + MTX | — | 12/76 (15.8%) | 76/76 (100%) |
| Event | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/29 | 1/76 |
| GangreneInfections and infestations | 1/29 | 0/76 |
| Pilonidal cystInfections and infestations | 1/29 | 0/76 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/29 | 1/76 |
| Joint effusionMusculoskeletal and connective tissue disorders | 1/29 | 0/76 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/29 | 0/76 |
| NeutropeniaBlood and lymphatic system disorders | 0/29 | 2/76 |
| Dysfunctional uterine bleedingReproductive system and breast disorders | 0/29 | 1/76 |
| ViremiaInfections and infestations | 0/29 | 1/76 |
| Aspartate aminotransferase increasedInvestigations | 0/29 | 1/76 |
| Event | Tocilizumab Monotherapy | Tocilizumab + MTX |
|---|---|---|
| Low density lipoprotein increasedInvestigations | 18/29 | 59/76 |
| Blood chloride increasedInvestigations | 16/29 | 55/76 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 17/29 | 21/76 |
| Blood cholesterol increasedInvestigations | 12/29 | 42/76 |
| Blood calcium decreasedInvestigations | 12/29 | 29/76 |
| Blood sodium increasedInvestigations | 11/29 | 28/76 |
| Blood triglycerides increasedInvestigations | 9/29 | 28/76 |
| AnaemiaBlood and lymphatic system disorders | 10/29 | 24/76 |
| Haematocrit decreasedInvestigations | 7/29 | 23/76 |
| Haemoglobin decreasedInvestigations | 8/29 | 15/76 |
| Age, Continuous(years) | Tocilizumab Monotherapy | Tocilizumab + MTX | Total |
|---|---|---|---|
| Mean | 37.78 ± 12.47 | 41.76 ± 11.84 | 40.64 ± 12.10 |
| Sex: Female, Male(Participants) | Tocilizumab Monotherapy | Tocilizumab + MTX | Total |
|---|---|---|---|
| Female | 23 | 69 | 92 |
| Male | 7 | 8 | 15 |
Ran from Feb 2010 to primary completion in Jan 2011, 10 months.
Results were first posted in Aug 2014, 3 years 6 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 10 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tocilizumab · Methotrexate